# CHART-C3G/CLNP023B12011

> **NCT07331259** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 83 (estimated)

## Conditions studied

- C3 Glomerulopathy
- Complement-mediated Kidney Disease
- Proteinuria

## Interventions

- **OTHER:** Iptacopan

## Key facts

- **NCT ID:** NCT07331259
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-03-01
- **Final completion:** 2027-03-01
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331259, "CHART-C3G/CLNP023B12011". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07331259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*